These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 18564621)

  • 41. Palonosetron (Helsinn).
    Stacher G
    Curr Opin Investig Drugs; 2002 Oct; 3(10):1502-7. PubMed ID: 12431027
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Are all 5-HT3 receptor antagonists the same?
    McNulty R
    J Natl Compr Canc Netw; 2007 Jan; 5(1):35-43. PubMed ID: 17239324
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A combination of aprepitant, palonosetron, and dexamethasone prevents emesis associated with anthracycline-containing regimens for patients with breast cancer. A retrospective study.
    Nakayama Y; Ito Y; Tanabe M; Takahashi S; Hatake K
    Breast Cancer; 2015 Mar; 22(2):177-84. PubMed ID: 23653153
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists.
    Babaoglu MO; Bayar B; Aynacioglu AS; Kerb R; Abali H; Celik I; Bozkurt A
    Clin Pharmacol Ther; 2005 Dec; 78(6):619-26. PubMed ID: 16338277
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis.
    Zhang Y; Yang Y; Zhang Z; Fang W; Kang S; Luo Y; Sheng J; Zhan J; Hong S; Huang Y; Zhou N; Zhao H; Zhang L
    J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27795228
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Palonosetron plus dexamethasone in highly emetogenic chemotherapy: pooled data from two Phase III trials.
    Celio L; Agustoni F; Ricchini F; Dotti K; Niger M; Braud FD
    Future Oncol; 2013 Oct; 9(10):1451-8. PubMed ID: 24106896
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting.
    Mori-Vogt S; Blazer M
    Expert Rev Anticancer Ther; 2013 Aug; 13(8):919-36. PubMed ID: 23984894
    [TBL] [Abstract][Full Text] [Related]  

  • 48. WITHDRAWN: Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
    Billio A; Morello E; Clarke MJ
    Cochrane Database Syst Rev; 2013 Dec; 2013(12):CD006272. PubMed ID: 24323437
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis.
    Jordan K; Hinke A; Grothey A; Voigt W; Arnold D; Wolf HH; Schmoll HJ
    Support Care Cancer; 2007 Sep; 15(9):1023-33. PubMed ID: 17205281
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron.
    Komatsu Y; Okita K; Yuki S; Furuhata T; Fukushima H; Masuko H; Kawamoto Y; Isobe H; Miyagishima T; Sasaki K; Nakamura M; Ohsaki Y; Nakajima J; Tateyama M; Eto K; Minami S; Yokoyama R; Iwanaga I; Shibuya H; Kudo M; Oba K; Takahashi Y
    Cancer Sci; 2015 Jul; 106(7):891-5. PubMed ID: 25872578
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy.
    Musso M; Scalone R; Bonanno V; Crescimanno A; Polizzi V; Porretto F; Bianchini C; Perrone T
    Support Care Cancer; 2009 Feb; 17(2):205-9. PubMed ID: 18839220
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience.
    Rzepecki P; Pielichowski W; Oborska S; Barzal J; Mlot B
    Transplant Proc; 2009 Oct; 41(8):3247-9. PubMed ID: 19857722
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
    Massidda B; Ionta MT
    J Chemother; 1996 Jun; 8(3):237-42. PubMed ID: 8808724
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Chemotherapy-induced emesis and serotonin antagonists].
    Jantunen I; Johansson R
    Duodecim; 1991; 107(14):1112-5. PubMed ID: 1670506
    [No Abstract]   [Full Text] [Related]  

  • 56. Palonosetron (Aloxi) for prevention of nausea and vomiting due to cancer chemotherapy.
    Med Lett Drugs Ther; 2004 Mar; 46(1179):27-8. PubMed ID: 15057189
    [No Abstract]   [Full Text] [Related]  

  • 57. Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.
    Kim KI; Lee DE; Cho I; Yoon JH; Yoon SS; Lee HS; Oh JM
    Ann Pharmacother; 2012 Dec; 46(12):1637-44. PubMed ID: 23170032
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Progress in preventing chemotherapy-induced nausea and vomiting.
    Markman M
    Cleve Clin J Med; 2002 Aug; 69(8):609-10, 612, 615-7. PubMed ID: 12184469
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of an increased-dose of dexamethasone in patients receiving fosaprepitant chemotherapy in Japan.
    Kumagai H; Kusaba H; Okumura Y; Komoda M; Nakano M; Tamura S; Uchida M; Nagata K; Arita S; Ariyama H; Takaishi S; Akashi K; Baba E
    Asian Pac J Cancer Prev; 2014; 15(1):461-5. PubMed ID: 24528075
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of palonosetron and ondansetron on preventing nausea and vomiting after laparoscopic surgery.
    Liu Q; Zhou C; Bao Z; Zhu Y
    J Int Med Res; 2018 Jan; 46(1):411-420. PubMed ID: 28718727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.